A first-in-class, first-in-human, phase I trial of CIGB-552, a synthetic peptide targeting COMMD1 to inhibit the oncogenic activity of NF-κB in patients with advanced solid tumors.
Vallespi MG, Mestre B, Marrero MA, Uranga R, Rey D, Lugiollo M, Betancourt M, Silva K, Corrales D, Lamadrid Y, Rodriguez Y, Maceo A, Chaviano PP, Lemos G, Cabrales A, Freyre FM, Santana H, Garay HE, Oliva B, Fernandez JR.
Vallespi MG, et al. Among authors: mestre b.
Int J Cancer. 2021 Sep 15;149(6):1313-1321. doi: 10.1002/ijc.33695. Epub 2021 May 27.
Int J Cancer. 2021.
PMID: 34019700
Clinical Trial.